These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 28511291)
41. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438 [TBL] [Abstract][Full Text] [Related]
42. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy. Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187 [TBL] [Abstract][Full Text] [Related]
43. Direct and Indirect Determinants of the Patient Global Assessment in Rheumatoid Arthritis: Differences by Level of Disease Activity. Ward MM; Guthrie LC; Dasgupta A Arthritis Care Res (Hoboken); 2017 Mar; 69(3):323-329. PubMed ID: 27273981 [TBL] [Abstract][Full Text] [Related]
44. Predictors of functional improvement and pain reduction in rheumatoid arthritis patients who achieved low disease activity with disease-modifying antirheumatic drugs: a retrospective study of the FIRST Registry. Ochi S; Sonomoto K; Nakayamada S; Tanaka Y Arthritis Res Ther; 2024 Jul; 26(1):140. PubMed ID: 39061106 [TBL] [Abstract][Full Text] [Related]
45. Rheumatoid arthritis patients with low baseline Health Assessment Questionnaire scores have a risk of functional disability progression: a post hoc analysis of a nationwide longitudinal cohort in Japan. Sumiyoshi R; Hidaka T; Koga T; Okada A; Fukuda T; Ishii T; Ueki Y; Kodera T; Nakashima M; Takahashi Y; Honda S; Horai Y; Watanabe R; Okuno H; Aramaki T; Izumiyama T; Takai O; Miyashita T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Kawakami A; Clin Exp Rheumatol; 2020; 38(6):1096-1101. PubMed ID: 32896260 [TBL] [Abstract][Full Text] [Related]
46. Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds. Nikiphorou E; Norton S; Young A; Carpenter L; Dixey J; Walsh DA; Kiely P; Ann Rheum Dis; 2016 Dec; 75(12):2080-2086. PubMed ID: 26979104 [TBL] [Abstract][Full Text] [Related]
47. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort. Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663 [TBL] [Abstract][Full Text] [Related]
48. Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study. Lutf A; Poil AR; Hammoudeh M Int J Rheum Dis; 2014 Jan; 17(1):63-5. PubMed ID: 24472269 [TBL] [Abstract][Full Text] [Related]
49. Time-averaged DAS28 and HAQ predict cardiovascular disease in patients with rheumatoid arthritis: Data from KORONA registry. Min HK; Kim HR; Lee SH; Kang KY; Park SH; Kwok SK Joint Bone Spine; 2022 Oct; 89(5):105401. PubMed ID: 35513231 [TBL] [Abstract][Full Text] [Related]
50. Improvements in Fatigue Lag Behind Disease Remission in Early Rheumatoid Arthritis: Results From the Canadian Early Arthritis Cohort. Holdren M; Schieir O; Bartlett SJ; Bessette L; Boire G; Hazlewood G; Hitchon CA; Keystone E; Tin D; Thorne C; Bykerk VP; Pope JE; Arthritis Rheumatol; 2021 Jan; 73(1):53-60. PubMed ID: 32852109 [TBL] [Abstract][Full Text] [Related]
51. Association of Body Mass Index Categories with Disease Activity and Radiographic Joint Damage in Rheumatoid Arthritis: A Systematic Review and Metaanalysis. Vidal C; Barnetche T; Morel J; Combe B; Daïen C J Rheumatol; 2015 Dec; 42(12):2261-9. PubMed ID: 26523023 [TBL] [Abstract][Full Text] [Related]
52. Latent Class Trajectory Modeling of 2-Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic Drugs. Dagliati A; Plant D; Nair N; Jani M; Amico B; Peek N; Morgan AW; Isaacs J; Wilson AG; Hyrich KL; Geifman N; Barton A; Arthritis Rheumatol; 2020 Oct; 72(10):1632-1642. PubMed ID: 32475078 [TBL] [Abstract][Full Text] [Related]
53. Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients. Curtis JR; Yang S; Chen L; Pope JE; Keystone EC; Haraoui B; Boire G; Thorne JC; Tin D; Hitchon CA; Bingham CO; Bykerk VP Arthritis Care Res (Hoboken); 2015 Oct; 67(10):1345-53. PubMed ID: 25988705 [TBL] [Abstract][Full Text] [Related]
54. Gain in quality-adjusted life-years in patients with rheumatoid arthritis during 1 year of biological therapy: a prospective study in clinical practice. Linde L; Sørensen J; Østergaard M; Hetland ML J Rheumatol; 2013 Sep; 40(9):1479-86. PubMed ID: 23818719 [TBL] [Abstract][Full Text] [Related]
56. Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data. Kim HL; Kim D; Jang EJ; Lee MY; Song HJ; Park SY; Cho SK; Sung YK; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim J; Kim SK; Kim TH; Kim TJ; Koh E; Lee H; Lee HS; Lee J; Lee SS; Lee SW; Park SH; Shim SC; Yoo DH; Yoon BY; Bae SC; Lee EK Rheumatol Int; 2016 Apr; 36(4):505-13. PubMed ID: 26849891 [TBL] [Abstract][Full Text] [Related]
57. American College of Rheumatology/European League Against Rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints. Kaneko Y; Kondo H; Takeuchi T J Rheumatol; 2013 Aug; 40(8):1254-8. PubMed ID: 23772077 [TBL] [Abstract][Full Text] [Related]
58. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M; Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405 [TBL] [Abstract][Full Text] [Related]
59. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. Welsing PM; Fransen J; van Riel PL Arthritis Rheum; 2005 Sep; 52(9):2616-24. PubMed ID: 16142762 [TBL] [Abstract][Full Text] [Related]
60. A randomised trial evaluating anakinra in early active rheumatoid arthritis. Scott IC; Ibrahim F; Simpson G; Kowalczyk A; White-Alao B; Hassell A; Plant M; Richards S; Walker D; Scott DL Clin Exp Rheumatol; 2016; 34(1):88-93. PubMed ID: 26842950 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]